Table 2.
Reference | 1a | 2 | 3 | 4 | 5 | 6a | 7 | 8 | 9 | 10 | 11 | Total |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Ulrich and Parstorfer [25] | – | 1 | 0 | 0 | 0 | – | 0 | 1 | 1 | 1 | 1 | 5/9 |
Judge et al. [26] | – | 1 | 0 | 0 | 0 | – | 0 | 1 | 1 | 1 | 1 | 5/9 |
West et al. [27] | – | 0 | 0 | 0 | 0 | – | 0 | 1 | 1 | 1 | 1 | 4/9 |
Tsolakis et al. [28] | – | 1 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 6/9 |
Ferreira et al. [29] | – | 1 | 0 | 0 | 0 | – | 0 | 1 | 1 | 1 | 1 | 5/9 |
Abbes et al. [30] | – | 1 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 6/9 |
Krzysztofik [31] | – | 1 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 6/9 |
Krzysztofik and Wilk [32] | – | 1 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 6/9 |
Markovic et al. [33] | – | 1 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 6/9 |
Brandenburg [34] | – | 1 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 6/9 |
Esformes et al. [35] | – | 1 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 6/9 |
Montoya et al. [36] | – | 1 | 0 | 0 | 0 | – | 0 | 1 | 1 | 1 | 1 | 5/9 |
Bellar et al. [37] | – | 1 | 0 | 0 | 0 | – | 0 | 1 | 1 | 1 | 1 | 5/9 |
Bevan et al. [38] | – | 0 | 0 | 0 | 0 | – | 0 | 1 | 1 | 1 | 1 | 4/9 |
Bodden et al. [39] | – | 1 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 6/9 |
Kilduff et al. [40] | – | 0 | 0 | 0 | 0 | – | 0 | 1 | 1 | 1 | 1 | 4/9 |
Liossis et al. [41] | – | 1 | 0 | 0 | 0 | – | 0 | 1 | 1 | 1 | 1 | 5/9 |
Judge et al. [42] | – | 1 | 0 | 0 | 0 | – | 0 | 1 | 1 | 1 | 1 | 5/9 |
Gilmore et al. [43] | – | 0 | 0 | 0 | 0 | – | 0 | 1 | 1 | 1 | 1 | 4/9 |
Hancock et al. [44] | – | 1 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 6/9 |
Barbosa et al. [45] | – | 1 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 6/9 |
Martinez-Garcia et al. [46] | – | 0 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 5/9 |
Gelen et al. [47] | – | 1 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 6/9 |
Cuenca-Fernandez et al. [48] | – | 1 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 6/9 |
Bliss et al. [49] | – | 0 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 5/9 |
Feros. 2020 [50] | – | 1 | 0 | 0 | 0 | – | 0 | 1 | 1 | 1 | 1 | 5/9 |
Higuchi et al. [51] | – | 0 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 5/9 |
Williams et al. [52] | – | 1 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 6/9 |
Sarramian et al. [53] | – | 0 | 0 | 0 | 0 | – | 0 | 1 | 1 | 1 | 1 | 4/9 |
Smilios et al. [54] | – | 1 | 0 | 1 | 0 | – | 0 | 1 | 1 | 1 | 1 | 6/9 |
Asencio et al. [55] | – | 1 | 0 | 0 | 0 | – | 0 | 1 | 1 | 1 | 1 | 5/9 |
1 = criterion was satisfied, 0 = criterion was not satisfied. Each satisfied criterion measure, excluding item 1 and 6, contributes 1 point to the total PEDro score (1–9). Criteria: (1) eligibility criteria were specified (anot applicable); (2) random allocation; (3) concealed allocation; (4) groups similar at baseline; (5) blinding of participants; (6) blinding of therapists who administered the therapy (anot applicable); (7) blinding of assessors; (8) less than 15% drop-outs; (9) intention to treat; (10) between-group statistical analysis; (11) point measures and variability data
PEDro Physiotherapy Evidence Database